BXCL501 After Stress to Increase Recovery Success
Phase 2
100
about 1.1 years
18–65
3 sites in FL, MO, VA
What this study is about
This trial is testing if BXCL501 helps reduce symptoms of Acute Stress Reaction (ASR) and Acute Stress Disorder (ASD) in adults who have experienced a motor vehicle collision. Participants will receive BXCL501 or a placebo after the accident, and their symptoms, cognitive function, and any side effects will be monitored over 396 days.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take BXCL501 (dexmedetomidine HCl)
- 2.Take Placebo
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
dexmedetomidine, Anesthetics (Adrenergic alpha1-Agonists)
Secondary: Change in Depressive Symptoms Score, Change in PTSD Symptoms, Change in Pain Symptom Score, Change in Somatic Symptom Score
Psychiatry / Mental Health